Sandoz Group AG: Sandoz to host capital markets day: maximising Sandoz value in its golden decade for biosimilars Montag, 22. Juni 2026 - 07:01

MEDIA RELEASE
 

Basel, 22 June 2026 – Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts:

• Tuesday, 8 September
• 13:30-17:00 UK time
• London Stock Exchange
• In-person and live webcast

The formal part of the event, webcast live, will begin at 13:30. In-person attendance will be by invitation only on a first-come, first-served basis; invitations will be distributed in due course. Details of how to access the live webcast are available here.

In addition, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, providing further insight into the Company’s new biosimilars development and supply-chain hub. Attendance will be by invitation only on a first-come, first-served basis; invitations will be distributed in due course. The event will not be webcasted.

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialise or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion.  

CONTACTS